National Registry and Cohort Study of Pulmonary Vascular Disease

Key facts

Sponsor

Nanjing First Hospital, Nanjing Medical University

Intervention

The clinical course and disease management(combination_product)

Enrollment

1000 enrolled

Eligibility

All sexes

Timeline

2022 – 2028

Study locations (13)

• Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
• Nanjing First Hospital, Nanjing, Jiangsu, China
• General Hospital of Tianjin Medical University, Tianjin, Tianjin Municipality, China
• Beijing Anzhen Hospital of Capital Medical University, Beijing, China
• China-japan Friendship Hospital, Beijing, China
• Xiangya Second Hospital, Central South University, Changsha, China
• West China Hospital, Sichuan University, Chendu, China
• Nanjing Drum Tower Hospital, Nanjing, China
• General Hospital of Northen Theater of Command, Shenyang, China
• Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China
• Zhongnan Hospital of Wuhan University, Wuhan, China
• First Affiliated Hospital of Xi'An Jiaotong University, Xi'an, China
• First Hospital of Zhengzhou University, Zhengzhou, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Drug- or toxin-induced pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06872112
  A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
  Joseph C. Wu
• RECRUITINGPHASE2NCT06351345
  129 Xenon Imaging in Patients Treated With Sotatercept
  Bastiaan Driehuys
• RECRUITINGPHASE4NCT07140484
  Sotatercept in Pulmonary Arterial Hypertension
  University of Alberta
• RECRUITINGPHASE2NCT07175038
  A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
  AllRock Bio, Inc.
• RECRUITINGNCT07013149
  The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
  University of Sao Paulo General Hospital
• RECRUITINGNCT06998329
  PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch
  University of Sao Paulo General Hospital
• ENROLLING BY INVITATIONPHASE2NCT06992440
  Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
  Gustavo A Heresi, MD, MS
• RECRUITINGNANCT06968962
  Comparison of Sequential to Initial Combination Therapy in PAH
  Second Affiliated Hospital, School of Medicine, Zhejiang University

See all trials for Drug- or toxin-induced pulmonary arterial hypertension →